UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 319, 2023

Comera Life Sciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware	1-41403	87-4706968
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
12 Gill StreetSuite 4650Woburn, Massachusetts		01801
(Address of principal executive offices)		(Zip Code)

12 Gill Street
Suite 4650
Woburn, Massachusetts

01801

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 871-2101

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CMRA	The Nasdaq Stock Market LLC
Warrants	CMRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 32.0102. ~~Notice~~Results of ~~Delisting~~Operations orand ~~Failure~~Financial ~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Condition.

On ~~October~~November 319, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) ~~received~~announced ~~notice~~via ~~from~~press ~~The~~release ~~Nasdaq~~its ~~Stock~~results ~~Market~~for ~~LLC that~~ the ~~Company~~third ~~had~~fiscal ~~not~~quarter ~~regained~~ended ~~compliance~~September ~~with~~30, ~~the $1~~2023.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (the “bid price requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) within the 180 calendar day period provided by Rule 5810(c)(3)(A) ~~and~~copy ~~that~~of the Company’s ispress ~~not~~release ~~eligible~~is ~~for~~hereby afurnished ~~second 180 day period~~ to ~~regain~~the ~~compliance~~U.S. ~~The~~Securities ~~notice~~and ~~letter~~Exchange ~~indicated~~Commission ~~that the Nasdaq Hearings Panel will consider this matter in their decision regarding the Company’s continued listing on the Nasdaq Capital Market~~ and ~~that~~incorporated ~~the~~herein ~~Company~~by ~~should~~reference ~~present~~as ~~its~~Exhibit ~~views with respect to this additional deficiency in writing no later than November 7, 2023~~99. 1.

~~As previously disclosed, the Company received a letter from the listing qualifications department staff of~~ The ~~Nasdaq~~information ~~Stock~~in ~~Market on November 18, 2022 notifying~~ the ~~Company~~press ~~that~~release ~~for~~attached ~~the~~hereto ~~last~~as 30Exhibit ~~consecutive~~99.1 ~~business~~is ~~days,~~intended ~~the~~to ~~Company’s~~be ~~minimum~~furnished ~~Market~~and ~~Value~~shall ofnot ~~Listed~~be ~~Securities~~deemed (“~~MVLS~~filed”) ~~was~~for ~~below~~purposes ~~the minimum~~ of ~~$35~~Section ~~million~~18 ~~required~~of ~~for continued listing on~~ the ~~Nasdaq~~Securities ~~Capital~~Exchange ~~Market~~Act ~~pursuant~~of to1934, ~~Nasdaq~~as ~~Listing~~amended ~~Rule 5550~~(~~b)(2).~~the On“Exchange ~~August 8~~Act”), ~~2023,~~or ~~the~~otherwise ~~Nasdaq~~subject ~~Hearings~~to ~~Panel granted~~ the ~~Company’s~~liabilities ~~request~~of ~~for~~that ~~the~~section, ~~continued~~nor ~~listing~~shall ofit ~~its~~be ~~common~~deemed ~~stock~~incorporated onby ~~the~~reference ~~Nasdaq~~in ~~Capital~~any ~~Market,~~filing ~~subject~~under to the ~~Company’s~~Securities ~~satisfaction~~Act of ~~certain~~1933, ~~interim~~as ~~milestones and~~amended, ~~ultimately,~~or the ~~Company’s~~Exchange ~~compliance with all applicable criteria for continued listing on Nasdaq~~Act, ~~including~~except ~~the~~as ~~bid~~expressly ~~price~~set ~~requirement~~forth ~~and the MVLS rule,~~ by nospecific ~~later~~reference ~~than~~in ~~November~~such ~~14, 2023~~filing.

~~The~~Item ~~Company~~9.01. ~~believes~~Financial itStatements ~~is unlikely to regain compliance with Nasdaq Listing Rules 5550(a)(2)~~ and ~~5550(b) by November 14, 2023, and therefore, its securities may be delisted from the Nasdaq Capital Market~~Exhibits.

If(d) ~~the~~Exhibits Company’s securities are delisted from the Nasdaq Capital Market, the Company will continue to be a reporting company under the Securities Exchange Act of 1934, as amended. In addition, the Company expects that its common stock will be traded on one of the three tiered marketplaces of the OTC Markets Group.

Forward-Looking Statements



Exhibit No.		Description

99.1		Press release dated November 9, 2023
	9
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

This Current Report on Form 8-K contains forward-looking statements that are based on the beliefs and assumptions of the Company’s management and on information currently available to the Company’s management. Forward-looking statements include statements regarding the Company’s efforts and ability to comply with all applicable criteria for continued listing on Nasdaq. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms. The Company’s ability to comply with the continued listing standards of Nasdaq, actual results and the timing of events could materially differ from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those described in more detail in the Company’s most recent Annual Report on Form 10-K and other documents on file with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 3, 2023

COMERA LIFE SCIENCES HOLDINGS, INC.

Dated: November 9, 2023

COMERA LIFE SCIENCES HOLDINGS, INC.

/s/ Michael Campbell

Michael Campbell

Executive Vice President and Chief Financial Officer

Filing Compare · Comera Life Sciences Holdings, Inc.